Friday, July 10, 2026

Drug profile · INN

clesrovimab-cfor

clesrovimab-cfor (ENFLONSIA) is an FDA-listed pharmaceutical active ingredient. Route of administration: solution. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — clesrovimab-cfor
US status
approved
Class
Route
SOLUTION
Patents
0
Programs
0
Data quality
0.84

Quick answer

clesrovimab-cfor (ENFLONSIA) is an FDA-listed pharmaceutical active ingredient. Route of administration: solution. Current US regulatory status: approved.

Key facts

INN clesrovimab-cfor
Brand ENFLONSIA
Route SOLUTION
Formulation INJECTION

Approval history

Authority Status Date
FDA approved

Frequently asked questions

What is clesrovimab-cfor?

clesrovimab-cfor (ENFLONSIA) is an FDA-listed pharmaceutical active ingredient. Route of administration: solution. Current US regulatory status: approved.

What is the brand name for clesrovimab-cfor?

ENFLONSIA is a marketed brand name for clesrovimab-cfor. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of clesrovimab-cfor?

clesrovimab-cfor has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.